She has been engaged in pharmaceutical innovation IP work for more than 18 years. Prior to joining Lilly, she served as a global IP responsible manager for multiple biologics’ projects at Tokyo headquarters of Astellas Pharmaceuticals. In 2014, she was invited byJapan Institute of Promoting Invention and Innovation (JIII)to write and publish a patent practice monograph of more than 200,000 words comparing the differences between Chinese and Japanese biological and chemical patent protection practices. Dr. He obtained a Bachelor of Clinical Medicineanda Master of Pharmacology in China and a Ph.D. of bioscience in Japan.
INTELLECTUAL PROPERTY SUMMIT OF GREAT INFLUENCE IN ASIA
Tel | 电话: +86 21 6765 8679
Mob.| 手机: +86 136-5189-8193
E-mail | 邮箱: CIPIS@conwaysasia.com
China Intellectual Property & Innovation Summit | 中国知识产权及创新峰会